Literature DB >> 30998819

Utility of Ophthalmologic Screening for Patients With Candida Bloodstream Infections: A Systematic Review.

Mark P Breazzano1,2,3, H Russell Day1, Karen C Bloch1,4, Sarah Tanaka1, Edward F Cherney1,2, Paul Sternberg1,2, Sean P Donahue1,2,5, John B Bond1,2.   

Abstract

Importance: The Infectious Diseases Society of America recommends ophthalmologic examinations for everyone with positive Candida blood culture results (candidemia) to screen for endophthalmitis, a practice that remains controversial because of multiple concerns for its limited usefulness and potential for harm. Objective: To determine guideline efficacy by reconciling discrepancies in the incidence of endophthalmitis and evaluating outcomes of studies assessing ophthalmologic screening for candidemia. Evidence Review: PubMed literature searches, including the search terms candidemia, fungemia, chorioretinitis, and endophthalmitis, identified longitudinal studies prior to 2018 of patients who underwent ophthalmologic evaluations in the setting of positive fungal blood culture results regardless of symptoms or clinical status. Additional studies not captured by these queries were found by manually scanning references within the articles captured by the queries. Ambiguous studies of patients with concomitant bacterial or viral infections were excluded. Findings: Thirty-eight applicable studies of 7472 patients who underwent ophthalmologic screening for candidemia or fungemia were identified. Criteria were compared with the conventional definition of endophthalmitis based on present (concordant) or absent (discordant) frank vitreous involvement. Concordant (59 of 6693 [0.9%]) and discordant (114 of 779 [14.6%]) endophthalmitis incidence rates differed by 13.8% (95% CI, 11.4%-16.4%; P < .001). Visual acuity for each case was recorded verbatim as subjective report provided by each study, when available. None of the concordant endophthalmitis cases reported direct, intraocular, microscopic evidence of Candida or other fungal organisms. Outcomes were available for 19 patients with concordant endophthalmitis; 6 died within 4 weeks of screening. The rate of substantial vision loss was associated (φ = 0.58; 95% CI, 0.01-0.86; P = .046) with additional invasive intervention (3 of 6 [50.0%]) compared with medical management alone (0 of 6). Conclusions and Relevance: In this systematic review without meta-analysis, inconsistent definitions of endophthalmitis accounted for discrepancies of its incidence and overreporting among patients with candidemia, contributing to bias and resulting in the construction of guidelines. As few as 3 of 7472 patients had potential improvement, while routine examination overall could lead to additional interventions and harm in this population. These findings suggest that indiscriminate screening based on candidemia alone does not appear to be supported by the literature and should be reevaluated for inclusion as a recommendation from the Infectious Diseases Society of America.

Entities:  

Mesh:

Year:  2019        PMID: 30998819     DOI: 10.1001/jamaophthalmol.2019.0733

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  13 in total

1.  National emergency department trends for endogenous endophthalmitis: an increasing public health challenge.

Authors:  Loka Thangamathesvaran; Joseph K Canner; Adrienne W Scott; Fasika A Woreta; Mark P Breazzano
Journal:  Eye (Lond)       Date:  2022-04-29       Impact factor: 3.775

2.  Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes.

Authors:  Kuan-Jen Chen; Ming-Hui Sun; Yen-Po Chen; Yi-Hsing Chen; Nan-Kai Wang; Laura Liu; An-Ning Chao; Wei-Chi Wu; Yih-Shiou Hwang; Chi-Chun Lai
Journal:  J Fungi (Basel)       Date:  2022-06-16

3.  Comment on: 'Incidence of chorioretinitis and endophthalmitis in hospitalized patients with fungemia'.

Authors:  Mark P Breazzano
Journal:  Eye (Lond)       Date:  2022-01-27       Impact factor: 4.456

Review 4.  Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.

Authors:  Melissa D Johnson; Russell E Lewis; Elizabeth S Dodds Ashley; Luis Ostrosky-Zeichner; Theoklis Zaoutis; George R Thompson; David R Andes; Thomas J Walsh; Peter G Pappas; Oliver A Cornely; John R Perfect; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2020-08-05       Impact factor: 5.226

5.  Choroidal origin of endogenous Candida endophthalmitis.

Authors:  Mark P Breazzano
Journal:  BMC Ophthalmol       Date:  2020-07-13       Impact factor: 2.209

6.  Effect of first-line antifungal treatment on ocular complication risk in Candida or yeast blood stream infection.

Authors:  Nina Hautala; Hannu Köykkä; Mira Siiskonen; Juho Saari; Jari Kauranen; Timo Hautala
Journal:  BMJ Open Ophthalmol       Date:  2021-09-16

7.  Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report.

Authors:  Edwin Chong Yu Sng; Ai Ling Tan; Peijun Yvonne Zhou; Tira J Tan; Samanthila Waduthantri; Soon-Phaik Chee; Ban Hock Tan
Journal:  Open Forum Infect Dis       Date:  2021-10-08       Impact factor: 3.835

8.  The Incidence of Ocular Complications in Candidemic Patients and Implications for the Practice of Routine 
Eye Exams.

Authors:  Molly Hillenbrand; Angelico Mendy; Kavya Patel; Racheal Wilkinson; Siyun Liao; Jamie Robertson; Senu Apewokin
Journal:  Open Forum Infect Dis       Date:  2022-03-19       Impact factor: 3.835

9.  Candida auris and endogenous panophthalmitis: clinical and histopathological features.

Authors:  Mark P Breazzano; Andrea A Tooley; Kyle J Godfrey; Codrin E Iacob; Nicolas A Yannuzzi; Harry W Flynn
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-11

10.  Endogenous Serratia marcescens panophthalmitis: A case series.

Authors:  Mark P Breazzano; Gowtham Jonna; Niraj R Nathan; Hilary H Nickols; Anita Agarwal
Journal:  Am J Ophthalmol Case Rep       Date:  2019-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.